Cyteir Therapeutics Eulerpool News

Cyteir Therapeutics Eulerpool News

Cyteir Therapeutics Stock News

Cyteir Therapeutics is being monitored by journalists and investors worldwide. We gather the latest Cyteir Therapeutics news here.

• March 7 ·

  Yahoo
  Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq
• March 7 ·

  Thefly.com
  Cyteir Therapeutics announces timeline for voluntarily delisting from Nasdaq
• February 20 ·

  Business Wire
  Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
• January 5 ·

  Thefly.com
  Cyteir Therapeutics downgraded to Underperform at BofA, coverage terminated
• November 1 ·

  Fintel
  Cyteir Therapeutics (CYT) Price Target Increased by 20.00% to 3.06
• October 12 ·

  Yahoo
  Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile
• October 12 ·

  Thefly.com
  Cyteir: Cohort of CYT-0851 in combo for ovarian cancer well tolerated
• September 18 ·

  SeekingAlpha
  Cyteir: Although The Company Is Winding Down, The Lead Asset Had Promise
• July 11 ·

  Fintel
  Fmr Now Owns 2.33% of Cyteir Therapeutics (CYT)
• July 6 ·

  Fintel
  Cyteir Therapeutics (CYT) Price Target Increased by 7.14% to 2.55